Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 80Leukemia 31Myelodysplastic Syndromes 19Leukemia, Myelomonocytic, Acute 14Leukemia, Monocytic, Acute 14Leukemia, Erythroblastic, Acute 14Leukemia, Megakaryoblastic, Acute 13Congenital Abnormalities 12Recurrence 6Leukemia, Promyelocytic, Acute 6Anemia, Refractory, with Excess of Blasts 6Leukemia, Eosinophilic, Acute 5Leukemia, Basophilic, Acute 5Leukemia, Myelomonocytic, Chronic 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasm, Residual 2Myeloproliferative Disorders 2Leukemia, Myelomonocytic, Juvenile 2Sarcoma, Myeloid 1Leukemia, Myeloid 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Disease Progression 1Disease 1Blast Crisis 1

Interventions

Cyclophosphamide 64Peripheral Blood Stem Cell Transplantation 57fludarabine phosphate 54Busulfan 43Tacrolimus 38Methotrexate 38Cytarabine 36Filgrastim 34Cyclosporine 33Mycophenolic Acid 32Antilymphocyte Serum 32Whole-Body Irradiation 27Radiotherapy 25Methylprednisolone 22Imatinib Mesylate 22Etoposide 22Melphalan 18Cord Blood Stem Cell Transplantation 17Thiotepa 12Dasatinib 12Flow Cytometry 11sargramostim 10merphos 10fludarabine 10Sirolimus 10Granulocyte Colony-Stimulating Factor 10Therapeutics 9Prednisone 9Decitabine 9Carboplatin 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Blast Crisis × Gemtuzumab × Clear all
NCT03589729 2026-05-22

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

M.D. Anderson Cancer Center

Phase 2 Recruiting
100 enrolled
MyeloidOther hematologic neoplasmSarcoma

Blast Crisis, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Sarcoma, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡